title: [Superselective intraarterial chemotherapy using low dose CBDCA and Pirarubicin with concurrent radiotherapy for head and neck cancer].
abstract: To study the effects of superselective intraarterial chemotherapy with low-dose CBDCA, Pirarubicin, and concurrent radiotherapy on head and neck cancer, we compared primary cancer response and histopathological effective grades in 66 patients (more than T2) divided into radical and preoperative radiotherapy groups. The radical group (n=33) showed a 75.7% response in primary cancer, i.e. 54.5% complete remission and 21.2% partial remission. The preoperative group (n = 33) showed 39.4% complete remission when the histopathological effective grade was higher, and 57.6% partial remission when the grade was lower. Cancer response was better in the oral cavity, mesopharynx, and hypopharynx than in the parasinus. In the preoperative group, 5-year overall survival was 84.4% when the effective grade was higher, and 29.4% when the grade was lower. Survival differed significantly (P<0.01) between higher and lower grades. Additional postoperative therapy is thus essential in patients with lower grades of histopathological effectiveness.
authors.affiliation: Clinic of Otorhinolaryngology, Matsue Red Cross Hospital, Shimane.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Ito
authors.forename: Hiromi
authors.initials: H
authors.lastname: Shiba
authors.forename: Kazunori
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Yasuomi
authors.initials: Y
authors.lastname: Kunimoto
authors.forename: Shunji
authors.initials: S
authors.lastname: Tanimoto
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Higami
authors.forename: Hiroya
authors.initials: H
authors.lastname: Kitano
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D004317:Doxorubicin; D016190:Carboplatin; C027260:pirarubicin